All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

When should we give JAK inhibitors to patients with MF in the peri-transplant setting?

During the 2021 TCT Meetings Digital Experience, the MPN Hub spoke to Ruben A. Mesa, UT Health San Antonio, San Antonio, US. We asked, When should we give JAK inhibitors to patients with myelofibrosis (MF) in the peri-transplant setting?

When should we give JAK inhibitors to patients with MF in the peri-transplant setting?

Points for discussion include whether the use of JAK inhibitors prior to transplant is helpful, whether to continue delivery throughout transplantation, and the benefit of using fedratinib as second line therapy.

Share: